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Colorectal cancer (CRC) is the second cause of 
cancer-related death worldwide. Surgery constitutes 
the primary therapy for these tumors, together with 
chemotherapy that is usually recommended in patients 
with metastatic primary CRC. Although molecularly 
distinct entities arising from different physiopathogenic 
mechanisms - microsatellite (MSI) and chromosomal 
instability (also called microsatellite stable, MSS) - have 
been  characterized  in  CRC,  there  is  still  no  specific 
therapeutic approach that takes into account disease’s 
molecular heterogeneity [1]. MSI is observed in 10-
15% of sporadic CRCs. MSI CRCs displayed particular 
morphologic features, with greater predilection for the 
right colon, mucinous histology, low metastatic power, 
poorer differentiation and higher numbers of tumor-
infiltrating  lymphocytes.  They  have  been  consistently 
reported to show an improved prognosis and a different 
response to chemotherapeutic agents. In a recent article in 
Nature Medicine, we have reported the specific mutation 
of the molecular chaperone HSP110 in MSI CRCs and 
how the presence of this mutant may constitute a first 
step towards the understanding of their particular clinical 
characteristics [2].
It  is  now  well  established  that  MMR  deficiency 
is not in itself a direct transforming event and that the 
development  of  these  tumors  is  MSI-driven.  This 
distinctive MSI pathway is characterized by somatic 
mutational events affecting short coding repeated 
sequences that, when having an oncogenic effect, provide 
selective pressure during tumor progression [3]. We 
showed that a T17 mononucleotide repeat located in intron 
8 of HSP110 was systematically mutated in MSI CRC 
cell lines and primary tumors [2]. The shortening of this 
repeat in tumor DNA correlated with increased synthesis 
of an aberrant HSP110 transcript due to exon 9 skipping, 
to the detriment of wild-type HSP110 mRNA. As a 
result, a truncated HSP110 mutant protein (HSP110DE9) 
accumulated in MSI tumors. Strikingly, we demonstrated 
that HSP110DE9 acts as a dominant negative mutant 
that binds to HSP110 abrogating its chaperone activity 
and cytoprotective function. In colon tumors, HSPs 
including HSP110 have been clearly shown to promote 
cancer cell survival, protecting oncogenic proteins 
and inhibiting apoptosis [4-6]. It is thus unclear why 
HSP110DE9 proapoptotic mutant is selected during MSI 
tumorigenesis. Long, noncoding mononucleotide repeats 
such  as  the T17 located in HSP110 intron 8 constitute 
hot spots for mutations in MSI tumors due to the MMR 
deficiency. Our hypothesis is that when these mutations 
are endowed with a biological anti-cancer activity, as 
it is the case with HSP110DE9, they can represent an 
Achilles’ heel in the MSI-driven tumorigenic process. 
Further studies are now necessary to determine the exact 
role of HSP110DE9 during MSI tumor progression and 
to understand the contribution of HSP110DE9 in the 
more favorable prognosis of CRC MSI compared to MSS 
patients.
In vitro, HSP110DE9 expression sensitized colon 
cancer cells to anticancer agents such as oxaliplatin 
and  5-fluorouracil,  which  are  routinely  prescribed  in 
the adjuvant treatment of patients with CRC [7]. In line 
with these results, we observed that MSI CRC patients 
with high HSP110DE9 expression levels who received 
chemotherapy were all associated with disease-free 
survival [2]. Therefore, HSP110DE9 levels are likely to 
constitute a crucial determinant for MSI CRC patients’ 
prognosis and treatment response. Because this mutant 
protein was expressed at variable levels in these tumors, 
our findings thus provide evidence for an additional layer 
of clinical heterogeneity among MSI colon cancers. 
Additional studies in larger populations are now being 
performed in order to confirm these results. MSI CRC 
patients have been recurrently reported to benefit less from 
5-FU treatment whereas they seem to show improved 
response to 5-FU-oxaliplatin (FOLFOX) that constitute 
today the gold standard of adjuvant chemotherapy in 
CRC. As Dr. Andrew T. Chan mentions in a recent issue 
in Nature Medicine [8], “it is fascinating to speculate 
that such studies might show a lack of response to 5-FU 
confined to the MSI CRCs with low levels of HSP110DE9”. 
In tumor samples, MSI phenotype can be determined 
by PCR according to international criteria or by 
immunohistochemistry studying mismatch repair (MMR) 
protein expression affecting MLH1, MSH2, MSH6 or 
PMS2. Our findings highlight that routine evaluation of 
the MSI phenotype together with investigation of HSP110 
status could be of clinical interest in CRC diagnosis. Note 
worthily, HSP110DE9 is the first HSP mutant identified 
in a cancer so far. Developing inhibitors of HSP110 
that mimic the anti-cancer chemosensitizing effect of 
HSP110DE9 is also a promising perspective.Oncotarget 2011; 2:  826 - 827 827 www.impactjournals.com/oncotarget
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